Header Logo

Connection

KENNETH MCCLAIN to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Antibodies, Monoclonal, Humanized.
KENNETH MCCLAIN
Connection Strength
0.316
Antibodies, Monoclonal, Humanized
  1. Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood Adv. 2023 07 25; 7(14):3725-3734.
    View in: PubMed
    Score: 0.145
  2. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017 Sep 01; 123(17):3229-3240.
    View in: PubMed
    Score: 0.095
  3. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013 Jan; 60(1):101-9.
    View in: PubMed
    Score: 0.066
  4. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Mar; 44(3):251-4.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.